Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of Jiangsu Yahong Meditech Co Ltd
No Price
Closing Price XSHG 29.04.2026:
12,85 CNY
29.04.2026 03:18
Current Prices from Jiangsu Yahong Meditech Co Ltd
Exchange
Ticker
Currency
Last Trade
Price
Daily Change
SSE
688176.SS
CNY
29.04.2026 03:18
12,85 CNY
0,12 CNY
+0,94 %
Share Float & Liquidity
Free Float99,99 %
Shares Float562,45 M
Shares Outstanding562,5 M
Company Profile for Jiangsu Yahong Meditech Co Ltd Share
Jiangsu Yahong Meditech Co., Ltd. engages in the research and development, production, and commercialization of drugs for genitourinary system tumors and other diseases in China and internationally. Its pipeline includes APL-1202, an anti-tumor drug, which is in Phase III clinical trial for the treatment of non-muscle invasive bladder cancer; APL-1501, an oral MetAP inhibitor that is in Phase I clinical trial for the treatment of urinary system tumors and drug-resistant urinary tract infections; APL-1706, an agent drug, which is in Phase III clinical trial for the treatment of non-muscle invasive bladder cancer; and APL-1702, a photodynamic therapy product that is in Phase III clinical trial for the treatment of cervical high-grade squamous intraepithelial lesions of the cervix caused by infection of HPV subtypes. In addition, it develops targeted protein degraders which are in preclinical stage comprising ASN-1764 for the treatment of triple negative breast cancer; ASN-1780 for the treatment of metastatic castration-resistant prostate cancer; and APL-1901 for the treatment of ER positive breast cancer. Further, the company develops APL-1401 to treat moderately to severely active ulcerative colitis; and ASN-1733 to treat acinetobacter baumannii infection. Jiangsu Yahong Meditech Co., Ltd. was founded in 2010 and is based in Shanghai, China.
